Evidence map›Paper›PMID 32705819›Full record

ArticleAnnals of clinical and translational neurology2020

PKAN neurodegeneration and residual PANK2 activities in patient erythrocytes.

Maike Werning, Ernst W Müllner, Georg Mlynek, Verena Dobretzberger, Kristina Djinovic-Carugo, David M Baron, Holger Prokisch, Boriana Büchner, Thomas Klopstock, Ulrich Salzer

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. [Research advances in the pathogenesis and treatment of neurodegeneration with brain iron accumulation].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2021
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Maike WerningCenter for Medical Biochemistry, Max Perutz Labs, Medical University of Vienna, Vienna, Austria.
Ernst W MüllnerCenter for Medical Biochemistry, Max Perutz Labs, Medical University of Vienna, Vienna, Austria.
Georg MlynekDepartment of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Vienna, Austria.
Verena DobretzbergerCenter for Medical Biochemistry, Max Perutz Labs, Medical University of Vienna, Vienna, Austria.
Kristina Djinovic-CarugoDepartment of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Vienna, Austria.
David M BaronDepartment of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Vienna, Austria.
Holger ProkischInstitute of Human Genetics, Technical University of Munich, Munich, Germany.
Boriana BüchnerDepartment of Neurology, Friedrich-Baur-Institute, University Hospital, LMU Munich, Munich, Germany.
Thomas KlopstockDepartment of Neurology, Friedrich-Baur-Institute, University Hospital, LMU Munich, Munich, Germany.
Ulrich SalzerCenter for Medical Biochemistry, Max Perutz Labs, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-3721-7225
Max Perutz Labs · ATUniversity of Vienna · ATFriedrich Baur Stiftung · DEGerman Center for Neurodegenerative Diseases · DEHelmholtz Zentrum München · DEMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePantothenate kinase 2-associated neurodegeneration (PKAN) is a rare neurodegenerative disease caused by mutations in the pantothenate kinase 2 (PANK2) gene. PKAN is associated with iron deposition in the basal ganglia and, occasionally, with the occurrence of misshaped erythrocytes (acanthocytes). The aim of this study was to assess residual activity of PANK2 in erythrocytes of PKAN patients and to correlate these data with the type of PANK2 mutations and the progression of neurodegeneration.

methodsResidual PANK2 activities in erythrocytes of 14 PKAN patients and 14 related carriers were assessed by a radiometric assay. Clinical data on neurodegeneration included the Barry-Albright Dystonia Scale (BAD-Scale) besides further general patient features. A molecular visualization and analysis program was used to rationalize the influence of the PKAN causing mutations on a molecular level.

resultsErythrocytes of PKAN patients had markedly reduced or no PANK2 activity. However, patients with at least one allele of the c.1583C > T (T528M) or the c.833G > T (R278L) variant exhibited 12-56% of residual PANK2 activity. In line, molecular modeling indicated only minor effects on enzyme structure for these point mutations. On average, these patients with c.1583C > T or c.833G > T variant had lower BAD scores corresponding to lower symptom severity than patients with other PANK2 point mutations.

interpretationResidual erythrocyte PANK2 activity could be a predictor for the progression of neurodegeneration in PKAN patients. Erythrocytes are an interesting patient-derived cell system with still underestimated diagnostic potential.

Indexed as

Disease ProgressionRegistriesAdolescentAdultBiological Specimen BanksErythrocytesFemaleHumansMalePantothenate Kinase-Associated NeurodegenerationPhosphotransferases (Alcohol Group Acceptor)PrognosisYoung Adultpantothenate kinasePhosphotransferases (Alcohol Group Acceptor)

Identifiers

PMID32705819
PMCPMC7448160
OpenAlexW3044467104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.